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Preventing post-partum haemorrhage at home during 
COVID-19: what are we waiting for?
Disruptions in health service delivery due to the 
COVID-19 pandemic have had a devastating effect on 
maternal, neonatal, and child health (MNCH) with rises 
in maternal and neonatal deaths expected.1 Post-partum 
haemorrhage is the leading cause of maternal mortality 
in low-income countries and is likely to increase because 
of estimates of, at best, a 10% reduction in MNCH 
services.1
Misoprostol is a safe and cost-effective alternative 
uterotonic that is used when oxytocin is not available. 
It is heat stable, available in tablet form, and can be 
distributed by a community health worker, traditional 
birth attendant, or taken by the woman herself after 
birth.2 In November, 2020, WHO recommended the 
advance distribution of misoprostol at antenatal visits 
for the prevention of post-partum haemorrhage for 
women who give birth at home and cannot access a 
skilled birth attendant.3
Advance distribution of misoprostol for the 
prevention of post-partum haemorrhage in contexts 
where women cannot access a health facility because 
of disruptions in essential health services, such as the 
COVID-19 pandemic, is now a crucial consideration. 
Misoprostol has previously been distributed in 
humanitarian emergencies where access to health 
services was difficult. During the 2014–16 Ebola 
outbreak in Liberia, misoprostol was included in clean 
birth kits and distributed by trained community health 
workers.4–6 Nepal, one of the first countries to scale 
up the use of misoprostol for the prevention of post-
partum haemorrhage in the community, continued to 
make use of this strategy during the 2015 earthquake.5,7
Scaling-up misoprostol for the prevention of post-
partum haemorrhage in the community in Nepal has 
again reaped benefits during the COVID-19 pandemic. 
Facility-based births were reduced by half (49·9%) 
during Nepal’s COVID-19 lockdown (between March 21 
and May 30, 2020).8 In May, 2020, the Nepalese Ministry 
of Health and Population approved the distribution of 
misoprostol to all women who cannot reach a health 
facility to give birth and were 8 months pregnant.9 This 
was expedited because women were facing difficulties 
in accessing maternal health services because of the 
lockdown and their reluctance to give birth at the health 
facility.
The examples during the Ebola outbreak in Liberia 
and recently in Nepal highlight that misoprostol can 
be distributed in complex emergencies where health 
systems have been disrupted. In both contexts, a cadre 
of trained community health workers assisted with 
distribution. Ministries of Health and partners, including 
Jhpiego in Liberia and One Heart Worldwide in Nepal, 
were able to quickly adapt and distribute misoprostol 
to women within the community. This ability to 
mobilise misoprostol was partly due to political support, 
previous experience, and evidence for the distribution 
at community level for post-partum haemorrhage 
prevention.2 In both countries, misoprostol for post-
partum haemorrhage was on the National Essential 
Medicines List and part of the essential MNCH drugs, 
alongside oxytocin. In the case of the Ebola outbreak in 
Liberia, available guidelines and recommendations by 
WHO and UNICEF probably accelerated its use.
The 2020 WHO guidelines affirm that misoprostol can 
be distributed in advance to women in humanitarian 
contexts with considerations to integration with other 
response strategies and the values and preferences of 
women in emergency situations.3 The Minimum Initial 
Services Package for Sexual and Reproductive Health 
is a response strategy that can be used to increase 
access to misoprostol for post-partum haemorrhage in 
humanitarian crises. The Inter-Agency Working Group 
on Reproductive Health in Crises also recommends pre-
positioning supplies of misoprostol for the prevention 
of post-partum haemorrhage and training and 
equipping community providers during COVID-19 in 
settings where health facilities are inaccessible.10
COVID-19 has shown that innovative mitigation 
strategies are needed to resume gains made in MNCH. 
Governments and policy makers need to update their 
national guidelines to ensure that misoprostol for post-
partum haemorrhage prevention can be distributed 
at the community level, at least until the pandemic 
improves. Community health workers and traditional 
birth attendants play a crucial role in bridging the 
service delivery gap and can provide clean delivery 
For more on Minimum Initial 
Services Package for Sexual and 
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kits that include misoprostol to prevent post-partum 
haemorrhage.
Now is the opportunity to ensure that all women 
in need can protect themselves against post-partum 
haemorrhage and reduce the risk of dying in childbirth. 
Misoprostol can prevent post-partum haemorrhage and 
save women’s lives. What are we waiting for?
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